Targeting Novel Signaling Pathways in B-cell Malignancies
This information was originally presented on September 21, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Explain the significance of targeting BCR signaling pathways in B-cell malignancies
- Interpret emerging data on novel investigational agents that target specific pathways involved in BCR signaling
Jeffrey Jones, MD, MPH
The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute
- 0.50 Participation
- 0.52 Nurse
- 0.50 Pharmacist
- 0.50 Physician